FDA approves GSK’s Incruse Ellipta
LONDON — GlaxoSmithKline on Wednesday announced that the Food and Drug Administration approved Incruse Ellipta (umeclidinium), which is used for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, or COPD, including chronic bronchitis and/or emphysema.
Umeclidinium is the company’s first once-daily anticholinergic, a type of bronchodilator also known as a long-acting muscarinic antagonis and is contained in the Ellipta inhaler. The FDA-approved strength is 62.5-mcg.
“We believe Incruse Ellipta, our first monotherapy in the anticholinergic class, will be an important once-daily treatment option for appropriate patients with COPD. GSK has a long-standing commitment to the development of respiratory medicines in order to offer physicians a choice of treatment options for their patients. We are delighted by this approval, and are looking forward to making Incruse Ellipta available for appropriate patients with COPD in the US," said Darrell Baker, SVP and head of GSK Global Respiratory Franchise.
GSK anticipates that launch activities in the United States will begin during fourth quarter 2014.
Peeps introduces mini variety
BETHLEHEM, Pa. — Peeps, a brand from Just Born Quality Confections, on Thursday announced the biggest new product launch in the company’s 61-year history. The new confection, Peeps Minis, will give consumers the chance to snack on mini-sized marshmallow chicks throughout the year.
The minis come in three flavors — strawberry creme, chocolate creme and sour watermelon — and will be available in a resealable 24-count stand-up bag in candy aisles.
"Peeps entry into the everyday candy category with Peeps Minis is the next big step in giving consumers a new way to express their Peepsonality year round," said Brian Bachrach, senior marketing manager. "Many of our fans grew up loving our iconic chicks and we are now providing an opportunity to enjoy Peeps in a size perfect for snacking that is sure to make every day a holiday."
Peeps Minis are available now for a suggested retail price of $3.99.
Rite Aid April sales up 4.9% to $2 billion
CAMP HILL, Pa. — Rite Aid on Thursday posted $2 billion for the four weeks ended April 26, 2014, representing a lift of 4.9%. Same-store sales increased 5% over the prior-year period.
April front-end same-store sales increased 4.7%, with 4.6% of the increase attributable to a shift in the timing of Easter, which fell on April 20 this year, compared with March 31 last year. Pharmacy same-store sales, which included an approximate 138 basis points negative impact from new generic introductions, increased 5.2%. Prescription count at comparable stores increased 2.3% over the prior-year period.
Prescription sales accounted for 67.9% of drug store sales, and third-party prescription sales represented 97.4% of pharmacy sales.
Same-store sales for the eight-week period ended April 26, 2014 increased 2.9% over the prior-year period. Front-end same-store sales decreased 0.2% while pharmacy same-store sales increased 4.3%. Prescription count at comparable stores increased 1.7% over the prior-year period.
Total drug store sales for the eight weeks ended April 26, 2014 increased 2.6% with sales of $3.9 billion. Prescription sales represented 68.7% of total drugstore sales, and third party prescription sales represented 97.4% of pharmacy sales.